Lumosa Therapeutics Co., Ltd. (TPEX: 6535)
Health Care · Pharmaceuticals · TW
NT$80.90
-6.04% today · -57.9% 1Y
Lumosa Therapeutics Co., Ltd. (TPEX: 6535) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $425.51M and employs 36 people.
Over the last twelve months the share price has lost 57.9%, trading between 80.40 and 329.50.
Tweenvest scores Lumosa Therapeutics Co., Ltd. across four factors: quality 32/100, value 53/100, growth 50/100. Its strongest factor is value.
6535 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $425.51M
- Revenue (TTM)
- $1.08M
- P/E
- —
- EPS
- -2.23
- Dividend yield
- —
- Beta (5Y)
- 0.11
- 52-week high
- NT$329.50
- 52-week low
- NT$80.40
- Avg volume (3M)
- —
- Shares outstanding
- 167.49M
- Employees
- 36
- Next earnings
- —
About Lumosa Therapeutics Co., Ltd.
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
- ISIN
- TW0006535008
- Founded
- 2000
- Listed since
- Jul 16, 2015
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.